Prophylactic Administration of Levosimendan in Patients Undergoing Coronary Surgery

• Status: Completed
• Trial end date: 2014-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The present pilot study aims to investigate the effectiveness of the preoperative infusion of levosimendan in patients with impaired left ventricular function undergoing coronary artery bypass grafting.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AHEPA University Hospital
• Collaborator: Orion Corporation, Orion Pharma
• Treatments: Simendan

Criteria

Inclusion Criteria:

• coronary artery disease which warrants myocardial revascularization with coronary artery bypass grafting according to current guidelines

• age < 79 years old

• left ventricular ejection fraction <= 40%

• informed patient's consent

Exclusion Criteria:

• age < 18 years old

• emergency surgery

• medical history of acute myocardial infarction with ST elevation (STEMI) less than 14 days old

• any severe comorbidity which increases the perioperative risk (i.e. neoplasia, rheumatoid arthritis, chronic obstructive pulmonary disease)

• need for valvular replacement surgery

• redo surgery

• serum creatinine > 2 mg/dl

• history of malignant cardiac arrhythmias